Back

Efficacy, safety and very long term recurrences of cavo-tricuspid isthmus-dependent atrial flutter ablation: a large multicenter observational study.

12 April 2026 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Atrial flutter ablation Catheter Ablation of Arrhythmias EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Massimiliano Manfrin

Bolzano Central Hospital, Bolzano (Italy)

7 More presentations in this session

Presentation thumbnail
From anatomy to ablation: intracardiac echocardiography-guided cavotricuspid isthmus morphology and procedural outcomes in typical atrial flutter
Doctor M. Gabarin (Hamilton, CA)
Abstract Slides Video
Presentation thumbnail
Comparing pulsed field electroporation and radiofrequency ablation for the treatment of atypical atrial flutter
Doctor S. Azevedo (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Predictors of recurrence after ablation of atypical atrial flutter: insights from a real-world cohort
Doctor S. Azevedo (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Predictors of outcome after catheter ablation of atypical atrial flutter
Doctor K. Janosi (Pecs, HU)
Abstract Slides Video
Presentation thumbnail
Atypical atrial flutter after AF ablation vs De Novo atypical flutter: are they the same?
Doctor S. Azevedo (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial flutter ablation

The Event

Event poster

EHRA 2026

12 April - 14 April 2026
You may be interested in
thumbnail
Congress Presentation
Outcomes after cavotricuspid isthmus ablation: predictors of new-onset atrial fibrillation and stroke according to anticoagulation strategy
thumbnail
Congress Presentation
Pulmonary vein isolation with or without empirical cavotricuspid isthmus ablation
thumbnail
Congress Presentation
Cavotricuspid isthmus ablation using a pentaspline pulsed field ablation catheter: one-year outcomes.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources